Biosense Webster Launches the OPTRELL™ Mapping Catheter with TRUEref™ Technology for Mapping of Complex Cardiac Arrhythmias

Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i  announced the U.S. launch of the OPTRELL™ Mapping Catheter with TRUEref™ Technology powered by the CARTO® 3 System. The OPTRELL™ Mapping Catheter is a high-density diagnostic catheter, with small electrodes arranged in a fixed array formation to provide high-definition electrophysiological mapping of complex cardiac arrhythmia cases like persistent atrial fibrillation (AFib), redo AFib ablation, atrial tachycardia, and ventricular tachycardia.

Cardiac arrhythmias are a growing epidemic. AFib is the most common type of cardiac arrhythmia and impacts nearly 40 million people worldwide, with up to 6 million of these individuals living in the U.S.1,2 AFib is a progressive disease, and if left untreated can get worse over time or lead to other serious complications like heart disease or stroke.3,4 Catheter ablation is a safe and effective procedure to restore the heart’s incorrect electrical signals, which causes an abnormal heart rhythm.